Efficacy and safety of telitacicept in the treatment of immunoglobulin a nephropathy: a real-world, single-center, retrospective study

作者：Lunju Luo, Yiyao Deng, Shuang Chen, Yuqi Yang, Lu Liu, Rui Zhang, Zhengsheng Li, Lu Yang, Yan Zha, Jing Yuan · 发表于：BMC Nephrology · 年份：2025 · DOI：10.1186/s12882-025-04680-5 · 被引用次数：3 · 研究领域：Renal Diseases and Glomerulopathies、Platelet Disorders and Treatments、Renal Transplantation Outcomes and Treatments

BACKGROUND: Immunoglobulin A nephropathy (IgAN), the most common glomerular disease, is characterized by immune complex deposition and abnormal complement system activation. Telitacicept targets B cells through multiple mechanisms, potentially offering therapeutic benefits in IgAN. This retrospective study aimed to evaluate the efficacy and safety of telitacicept. METHODS: Eleven patients with IgAN treated with telitacicept (160 mg, weekly) between August 2022 and December 2024 were included. The minimum follow-up period was 24 weeks, and the primary endpoint was renal remission rate at the final visit. RESULTS: Among the 11 patients, 6 (54.5%) achieved partial remission, including 3 (27.3%) with complete response. Following telitacicept treatment, 24-h proteinuria decreased from a baseline of 1.77 g/day (interquartile range [IQR]: 1.31-5.19 g/day) to 1.04 g/day (IQR: 0.27-1.41 g/day) at the last follow-up (P < 0.05), demonstrating a significant reduction in proteinuria. Urinary red blood cell counts decreased from 52.81 ± 110.95 to 9.62 ± 11.44 per high-power field. The main adverse reaction was an upper respiratory tract infection, with no serious events reported. CONCLUSION: This study provided preliminary evidence that telitacicept may reduce proteinuria in patients with IgAN, with no serious safety concerns observed during this study. These preliminary real-world findings support the potential role of telitacicept in IgAN management and warrant confirmation in prospectiv...